Schistosomiasis Treatment for Preschool Children

Download Profile PDF
At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: Top Industry Pharma
  • Initiator Type: Nonprofit foundation
  • Rare disease
  • Disease focus:
    Schistosomiasis
  • Location: International

Abstract

Currently, infants and very young children who are infected with schistosomiasis cannot receive adequate treatment. The standard praziquantel therapy is available only as oral tablets for adults and children from the age of six. Moreover, younger children cannot always swallow these tablets because of their size and bitter taste. A pediatric formulation is desperately needed to develop an adequate treatment for the most vulnerable age group. This has led to the establishment of the first international public-private partnership in schistosomiasis. The objective of this partnership is to develop a formulation of praziquantel more suited to young children.

Sponsors & Partners

All the partners are highly motivated to address the need to treat schistosomiasis in very young children, some of whom are only three months old when they become infected. The new pediatric dosage of praziquantel will make an important contribution to the better control and potential elimination of this neglected tropical disease.

Homepage

http://www.tipharma.com/pharmaceutical-research-projects/completed-projects/schistosomiasis.html

Merck

Astellas Pharma Inc.

Swiss TPH

TI Pharma

Last Updated: 04/15/2016
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.